Select Page

First FDA Approved Targeted RNA-based Therapy

by | Aug 16, 2018 | Alerts

The U.S. FDA approved the first of its kind targeted RNA-based therapy Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) caused from hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA approved treatment...